Fresenius closes Merck biosimilar biz purchase

Fresenius Kabi said today that it closed its acquisition of Merck KGaA’s biosimilars unit.

The company paid €156 million at closing ($185.7 million USD) and could pay up to €500 million ($595.2 million USD) in milestone payments, which are contingent upon meeting certain drug development targets.

Get the full story at our sister site, Drug Delivery Business News.

The post Fresenius closes Merck biosimilar biz purchase appeared first on MassDevice.

from MassDevice http://ift.tt/2ev6RCY